



Compliance Alert

November 5, 2009

Express Scripts – Urgent –Emerging Therapeutic Issues Communication

Recently, Qualitest Pharmaceuticals issued a voluntary nationwide recall for all Accusure® Insulin Syringes. The syringes have been found to have needles which can detach from the syringe. When the needle becomes detached from the syringe during use, it can become stuck in the insulin vial, push back into the syringe, or remain in the skin after an injection. Consumers who have any recalled Accusure Insulin Syringes should stop using them and contact Qualitest at 1.800.444.4011 for reimbursement.

If you have additional questions, you can call Qualitest at 1.800.444.4011 for more information.

Additional information can be found on FDA's Medwatch website at: www.fda.gov/medwatch . You can also call FDA at 1.888.INFO.FDA (automated) or 301.796.3400.

Express Scripts' response:

- In an effort to inform members of this recall, we have identified members who have received a prescription for Accusure Syringes manufactured by Qualitest within the past 180 days. A communication summarizing the information provided by the manufacturer will be sent to these members.
- The above communication will be distributed for those clients enrolled in the member portion of the Emerging Therapeutic Issues Patient Safety Program.
- Express Scripts will also distribute letters to all patients who have filled a prescription for recalled syringes using Express Scripts Home Delivery services.

If you have any questions regarding this information, please contact your Group Benefit Services Account Manager at 1.800.638.6085.

This communication is not intended to be legal advice and should not be construed as legal advice. If you have any legal questions or concerns about your plan, GBS recommends seeking counsel from an ERISA attorney.

Keeping you informed. Just one more reason to choose GBS.